<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/jefferies-financial-group-equities-analysts-lower-earnings-estimates-for-medtronic-plc-nysemdt.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T01:52:55+00:00"/>
    <meta property="og:title" content="Jefferies Financial Group Equities Analysts Lower Earnings Estimates for Medtronic PLC (NYSE:MDT)"/>
    <meta property="og:description" content="Medtronic PLC (NYSE:MDT) – Research analysts at Jefferies Financial Group lowered their Q4 2020 earnings per share estimates for shares of Medtronic in a research note issued to investors on Wednesday, November 20th. Jefferies Financial Group analyst R. Denhoy now anticipates that the medical technology company will earn $1.63 per share for the quarter, down […]"/>
  </head>
  <body>
    <article>
      <h1>Jefferies Financial Group Equities Analysts Lower Earnings Estimates for Medtronic PLC (NYSE:MDT)</h1>
      <address><time datetime="2019-11-24T01:52:55+00:00">24 Nov 2019, 01:52</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/medtronic-inc-logo.jpg"/>
      </figure>
      <p>Medtronic PLC (NYSE:MDT) – Research analysts at Jefferies Financial Group lowered their Q4 2020 earnings per share estimates for shares of Medtronic in a research note issued to investors on Wednesday, November 20th. Jefferies Financial Group analyst R. Denhoy now anticipates that the medical technology company will earn $1.63 per share for the quarter, down from their previous estimate of $1.66. Jefferies Financial Group also issued estimates for Medtronic’s FY2022 earnings at $6.52 EPS.</p>
      <p>Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 19th. The medical technology company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $7.71 billion during the quarter, compared to the consensus estimate of $7.66 billion. Medtronic had a return on equity of 14.52% and a net margin of 15.11%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.22 earnings per share.</p>
      <p>Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus upped their price objective on Medtronic from $95.00 to $112.00 and gave the company a “hold” rating in a report on Wednesday, August 21st. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=MDT">ValuEngine</a> downgraded Medtronic from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo &amp; Co upped their price objective on Medtronic from $110.00 to $120.00 and gave the company an “outperform” rating in a report on Wednesday, August 21st. Raymond James upped their price objective on Medtronic from $118.00 to $121.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Deutsche Bank upped their price objective on Medtronic from $118.00 to $123.00 and gave the company a “buy” rating in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Medtronic currently has an average rating of “Buy” and an average target price of $116.58.</p>
      <p><a href="https://www.marketbeat.com/stocks/NYSE/MDT/earnings/">NYSE MDT</a> opened at $110.82 on Friday. The stock has a 50-day simple moving average of $108.04 and a 200 day simple moving average of $102.20. The company has a market capitalization of $148.24 billion, a PE ratio of 21.23, a P/E/G ratio of 2.68 and a beta of 0.62. The company has a current ratio of 2.77, a quick ratio of 2.20 and a debt-to-equity ratio of 0.49. Medtronic has a 12 month low of $81.66 and a 12 month high of $114.46.</p>
      <p>Large investors have recently bought and sold shares of the business. Nachman Norwood &amp; Parrott Inc boosted its position in Medtronic by 1.9% during the third quarter. Nachman Norwood &amp; Parrott Inc now owns 5,400 shares of the medical technology company’s stock valued at $587,000 after purchasing an additional 99 shares during the last quarter. Folger Nolan Fleming Douglas Capital Management Inc. boosted its position in Medtronic by 2.1% during the second quarter. Folger Nolan Fleming Douglas Capital Management Inc. now owns 4,782 shares of the medical technology company’s stock valued at $466,000 after purchasing an additional 100 shares during the last quarter. Pekin Hardy Strauss Inc. boosted its position in Medtronic by 1.5% during the second quarter. Pekin Hardy Strauss Inc. now owns 6,773 shares of the medical technology company’s stock valued at $660,000 after purchasing an additional 100 shares during the last quarter. Doliver Advisors LP boosted its position in Medtronic by 2.2% during the third quarter. Doliver Advisors LP now owns 4,705 shares of the medical technology company’s stock valued at $509,000 after purchasing an additional 100 shares during the last quarter. Finally, Affiance Financial LLC boosted its position in Medtronic by 1.3% during the third quarter. Affiance Financial LLC now owns 8,074 shares of the medical technology company’s stock valued at $877,000 after purchasing an additional 102 shares during the last quarter. 80.77% of the stock is owned by hedge funds and other institutional investors.</p>
      <p>In other Medtronic news, EVP Robert John White sold 52,165 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $109.33, for a total value of $5,703,199.45. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through <a href="https://www.sec.gov/Archives/edgar/data/1233311/000112760219031732/xslF345X03/form4.xml">this hyperlink</a>. Also, EVP Michael J. Coyle sold 2,102 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $109.77, for a total value of $230,736.54. Following the completion of the transaction, the executive vice president now directly owns 189,162 shares of the company’s stock, valued at $20,764,312.74. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/1233311/000112760219033063/xslF345X03/form4.xml">here</a>. Over the last three months, insiders sold 158,569 shares of company stock valued at $17,130,869. Insiders own 0.28% of the company’s stock.</p>
      <p>
        <b>Medtronic Company Profile</b>
      </p>
      <p>Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/what-are-faang-stocks/">What is the outlook for the FAANG stocks?</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=MDT"/>
      </figure>
    </article>
  </body>
</html>